Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy
Biohaven reported positive Phase 1b data for BHV-1300 in Graves' disease, showing >80% reduction in pathogenic TSHR-IgG1 antibodies and normalization of thyroid hormones within 3-5 weeks. For IgA nephropathy, BHV-1400 achieved >60% reduction in pathogenic Gd-IgA1 within 48 hours and 70% within one month, with associated improvements in kidney function markers (eGFR, UPCR).
Key figures
- Drug Name
- BHV-1300, BHV-1400
- Phase Of Trial
- Phase 1b
- Tshr igg1 reduction
- >80%
- Gd iga1 reduction 48h
- >60%
- Gd iga1 reduction 1month
- 70%
- T3 normalization median weeks
- 5
- T4 normalization median weeks
- 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.